Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:SYK

Stryker Corp. (SYK)

312.20
+6.56 (2.15%)
as of Jun 12, 2026, 8:00:00 pm Market Open.
258 watching
0
Investor Insights
star iconJun 12, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Stryker Corp. (SYK) faces challenges, including the recent cybersecurity incident affecting production and overall weakness in the health sector, but maintains a strong reputation as a leader in medical devices, particularly in orthopedics. Analysts highlight the attractiveness of the stock’s valuation, with expectations of significant earnings growth, forecasting $15 EPS by 2027 at a 20x PE ratio, driven by a 10% topline growth amidst an aging population. With a consistent market share gain from competitors like JNJ and ZBH, Stryker’s focus on robot-assisted surgeries in orthopedics is expected to double in growth over five years. Despite the current struggles in medtech, experts believe holding onto the stock could be beneficial in the long term, given its strong fundamentals and solid track record of acquisitions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
ZBH
TOP PICK

Stryker makes replacement body parts with several components involved. There is a huge backlog of elective surgeries due to Covid. Also an aging population needs more of these artificial parts so there is lots of growth ahead. Surgeons tend to use the same parts rather than switching to other makes. It has a great balance sheet and may make more acquisitions to grow the business. There may be some cost issues to deal with but this shouldn't be a problem. 70% of its business comes from the U.S.             Buy 17  Hold 12  Sell 1

BUY

Great business with aging population.
Bullish on healthcare sector.
Good time to buy for long term investor.
Strong fundamentals. 

BUY

They just reported a good quarter. They have solid growth; there will be more surgeries through the backlog.

BUY

Beneficiaries of increase in procedures since Covid. Replacement parts plus equipment. Never a cheap stock, but going into a growth period. Wouldn't hesitate to recommend it as part of a portfolio. Quality, well managed.

COMMENT

The caller was wondering whether to sell Johnson and Johnson and buy Stryker. Both are good companies and good for recessionary times. Johnson and Johnson is a consumer staple which sometimes has trouble with margins. He owns Stryker, a well run company.

PAST TOP PICK
(A Top Pick Feb 18/20, Up 39%)

Covid-induced backlog of surgeries is being tackled, and this benefits SYK, as it supplies both equipment and replacement joints. Innovative. 

TOP PICK

Things are back to normal. Best way to play the aging population. Market leader with best products and relationships with surgeons. Lots of potential globally. Sees tremendous growth ahead. Yield is 1.02%.

BUY

He just bought it. Though healthcare is down 3% YTD, he likes the medical devices space. Medical procedures are coming back. He likes the orthopedic and spine segment of their business, a strong catalyst. Also, supply chains have eased to expand their margins, plus the stock has momentum. Up 20% YTD with more upside ahead.

BUY

They reported top and bottom line growth and organic growth was better than expected. He's bullish about medical devices, given the Covid-induced backlog in surgeries.

TOP PICK

Medical device business very strong - high growth area. 
Healthcare sector demand not slowing down.
Aging baby boomer population will require further healthcare.
Need for increased healthcare tech. 

TOP PICK

It makes artificial joints and all kinds of specialized medical equipment. It is focused on many areas including hips, knees, ankles, etc. He especially likes the robotic assisted surgery component.     Buy 16  Hold 12  Sell 2

PAST TOP PICK
(A Top Pick Mar 16/22, Up 0.1%)

Fell a lot through Covid decline in elective surgeries. Great place to be over the long term. Aging demographics in its favour.

BUY

They make artificial hips and knees--a major growth area as the population ages. It pays a minor dividend, is profitable and performance has been strong over 5 years, up 63%. Great long term, given demographics.

DON'T BUY

Joint replacements and instrumentation business. Has come back in the latest rally. Good operators, but struggle for space in the operating room. Until that resolves, he'd shy away.

PAST TOP PICK
(A Top Pick Mar 16/22, Down 2%) Great business. Backlog in elective surgeries due to Covid will lead to good earnings growth going forward. Good growth internationally. Demographic play. Loyal customer base. Great medical device story.
Showing 31 to 45 of 170 entries